In this groundbreaking episode, we will dive into OpenAI’s latest leap from chatbots to biological AI with their new model, GPT-4 B Micro, designed to revolutionize longevity research. Discover how this innovation could turbocharge stem cell production, combat aging, and reshape regenerative medicine—all while unpacking Sam Altman’s $555 million bet on life extension startups.

Key Topics Covered:

OpenAI’s Biological AI Model: How GPT-4 B Micro improves Yamanaka factors to reprogram cells 50x more efficiently—a potential game-changer for anti-aging.
Sam Altman’s Longevity Obsession: His $180M investment in Retro Biosciences, a startup aiming to add 10+ years to human lifespan through cellular reprogramming and AI.
The Science of Immortality: Breaking down stem cell magic, age-related diseases, and why Silicon Valley giants like Google and Jeff Bezos are pouring billions into longevity.
Ethical Dilemmas: Altman’s cautionary stance on balancing AI’s power to “cure diseases or create new ones.”
Industry Trends: From Calico Life Sciences to Altos Labs, why tech moguls are betting big on turning aging from “inevitable” to “treatable.”

Join Julia for an in-depth discussion on one of the most critical challenges facing the future of AI development and economic prosperity.

Connect with Julia:

YouTube: https://youtube.com/juliamccoy

Instagram: https://www.instagram.com/juliaemccoy/

X: https://x.com/juliaemccoy